Future searches for feasible genetic markers may include brain tumor-specific splice variants of CD44, since they appear to be expressed on astrocytomas and glioblastomas and differ from known variants of leukocytes [90] (Eibl et al., unpublished). Here, CD44 is linked to astrocytoma (excluding glioblastoma).